• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability

    Machining & Laser Processing Have Huge Parts to Play in Medtech Manufacturing

    Medtech R&D Teams Must Be Creative & Resilient to Survive

    Struggling Suppliers in Electronics Manufacturing Services (EMS)

    Deep (Brain) Thoughts with Medtronic's Neuromodulation President
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    PDC Unveils New Brand Identity

    MD&M West News: Teamvantage Launches New Parent Company

    BD Receives EUA from FDA for COVID-19, Influenza A/B, RSV Combination Test

    Qosina Names Lee Pochter as Executive Vice President

    FDA Okays Early Feasibility Study for Anteris' TAVR Product
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability

    Machining & Laser Processing Have Huge Parts to Play in Medtech Manufacturing

    Medtech R&D Teams Must Be Creative & Resilient to Survive

    Struggling Suppliers in Electronics Manufacturing Services (EMS)

    Deep (Brain) Thoughts with Medtronic's Neuromodulation President
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Deducing the Dual Reality of Elizabeth Holmes

    The Return of the AdvaMed MedTech Conference…Live!

    Material Matters: New Materials Call for New Thinking

    5 Ways to Maintain a Talent-Centric Mindset, Even During Economic Uncertainty

    The Changing Face of UK Medical Device Regulations: Most Recent Update
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Halkey-Roberts Corporation

    NDH Medical Inc.

    LEMO USA Inc.

    Fusion Biotec Inc.

    Forefront Medical Technology
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Onshoring Medical Device Manufacturing Can Strengthen Supply Chains

    How Artificial Intelligence Can Combat Key Issues Impacting Healthcare

    Why Advanced Sensors Are Crucial Within Medical Pumps

    How Artificial Intelligence Could Help Prevent 80% of Chronic Diseases

    4 Ways to Use Injection Molding in Medical Device Manufacturing
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Halkey-Roberts Corporation

    NDH Medical Inc.

    LEMO USA Inc.

    Fusion Biotec Inc.

    Forefront Medical Technology
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Comparing cGMP Pharma vs. Device: Subpart E—Control of Components, Containers and Closures

    ...

    Comparing cGMP Pharma vs. Device: Subpart E—Control of Components, Containers and Closures
    Related Content
    • Benefits of Outsourcing IVD Assay Manufacturing
    • Comparing cGMP Pharma vs. Device: Subpart C—Buildings and Facilities and Subpart D—Equipment
    • Comparing cGMP Pharma vs. Device: Subpart B—Organization and Personnel
    • Comparing cGMP Pharma vs. Device: Subpart A—General Provisions (Part II)
    James A. Dunning, Owner, QPC Services LLC11.07.17
    Anyone working in the pharmaceutical and/or medical device industries knows that both sectors are very dynamic markets. Each is unique in its own way, but the two share a common goal of bringing safe, effective products to market as quickly and efficiently as possible.

    I’ve spent much of this year comparing parts of the drug and device industries’ Current Good Manufacturing Practices (cGMP) requirements, hoping to enlighten readers on the similarities I believe exist within the mandates. Clearly, the product approval process for drugs and devices is different, but both require knowledge of the proper documentation as well as an understanding of the elements for regulatory submission. Understanding the similarities and differences between the cGMP mandates is important for companies straddling both industries with combination drug-device products.   

    To conclude this cGMP comparison series, I will focus on ways 21 CFR Part 820 Quality System Regulation, also known as the cGMP regulation for medical devices, aligns with the cGMP requirements of 21 CFR Part 211 Subpart E —Control of Components and Drug Product Containers and Closures.  As was the case in previous articles, the term “pharmaceutical(s)” is used rather than “drug(s)” unless the term is part of an excerpt from the cGMP regulation. Scope and definition are the same as well.

    The first notable difference is the Pharmaceutical cGMP requirements are more specific in identifying drug product components, containers, and closures. The equivalent Medical Device cGMP mandates are more general, specifying requirements in terms of device specifications and process controls.

    The second item of note is the Medical Device cGMP requirements do not contain a directive for retesting approved components. Subpart L—covering Handling, Storage, Distribution, and Installation—instructs the manufacturer to ensure that mixups, damage, deterioration, contamination, or other adverse effects to a product do not occur during handling, (820.140 Handling). However, retesting is not a specific requirement. In my experience, medical device companies manufacturing products with components susceptible to deterioration over time will perform retesting. This is particularly the case with combination devices.

    Also of significance is the fact that Pharmaceutical cGMP requirement 211.94 (drug product containers and closures) is addressed in the Medical Device cGMP mandate 820.30 (design controls). Pharmaceutical design and development is a comprehensive process separate from the cGMP requirements. The comparison between the Pharmaceutical cGMP directive specified in 211.94 and the corresponding Medical Device cGMP requisites warrant a deeper dive. To make this analysis easier to follow, I cite the design controls process as 820.30(f) Design verification rather than mention all 820.30 requirements that would apply.

    Pharmaceutical cGMP 211.94(a)
    Drug product containers and closures shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug beyond the official or established requirements.

    Medical Device cGMP 820.30(f) Design verification
    Comments: The Pharmaceutical cGMP requirement is more specific in this section, stating the containers and closure should not be reactive, additive, or absorptive. The Medical Device cGMP in this section is more general, saying the design verification must confirm that design output meets design input requirements. If design activities determine components are not reactive, additive, or absorptive, then these requirements would be design inputs that are converted into specific design outputs and verified in accordance with 820.30(f) Design verification.

    Pharmaceutical cGMP 211.94(b)
    Container closure systems shall provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.

    Medical Device cGMP 820.30(f) Design verification, 820.130 Device packaging, and 820.150 Storage, paragraph (a)
    Comments: The storage requirements defined in 211.94(b) are addressed in the Medical Device design control requirements. Storage condition requisites are also specified in 820.130 Device packaging, which reads, “Each manufacturer shall ensure that device packaging and shipping containers are designed and constructed to protect the device from alteration or damage during the customary conditions of processing, storage, handling, and distribution.” Storage requirements are also specified in 820.150 Storage, which reads, “(a) Each manufacturer shall establish and maintain procedures for the control of storage areas and stock rooms for product to prevent mixups, damage, deterioration, contamination, or other adverse effects pending use or distribution and to ensure that no obsolete, rejected, or deteriorated product is used or distributed. When the quality of product deteriorates over time, it shall be stored in a manner to facilitate proper stock rotation, and its condition shall be assessed as appropriate.”

    Pharmaceutical cGMP 211.94(c)
    Drug product containers and closures shall be clean and, where indicated by the nature of the drug, sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use. Such depyrogenation processes shall be validated.

    Medical Device cGMP 820.30(f) Design verification, 820.75 Process validation
    Comments: Medical device manufacturers are mandated to use the design process to establish that components must be pyrogen-free. Process validation, which would include sterilization and cleaning processes, is also required by the Medical Device cGMP requirements. 

    Pharmaceutical cGMP 211.94(d)
    Standards or specifications, methods of testing, and, where indicated, methods of cleaning, sterilizing, and processing to remove pyrogenic properties shall be written and followed for drug product containers and closures.

    Medical Device cGMP 820.30(f) Design verification.  820.3(o) Definition of Manufacturer, and 820.75(a) Process Validation
    Comments: This requirement is addressed through the design process. Additionally, 820.3 Definitions, paragraph (o), states “Manufacturer means any person who designs, manufactures, fabricates, assembles, or processes a finished device. Manufacturer includes but is not limited to those who perform the functions of contract sterilization, installation, relabeling, remanufacturing, repacking, or specification development, and initial distributors of foreign entities performing these functions.” Finally, 820.75(a) Process validation reads “(a) Where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures. The validation activities and results, including the date and signature of the individual(s) approving the validation and where appropriate the major equipment validated, shall be documented.” 

    Pharmaceutical cGMP 211.94(e)
    Medical gas containers and closures must meet the following requirements—(1) Gas-specific use outlet connections. Portable cryogenic medical gas containers that are not manufactured with permanent gas use outlet connections (e.g., those that have been silver-brazed) must have gas-specific use outlet connections that are attached to the valve body so that they cannot be readily removed or replaced (without making the valve inoperable and preventing the containers’ use) except by the manufacturer. For the purposes of this paragraph, the term “manufacturer” includes any individual or firm that fills high-pressure medical gas cylinders or cryogenic medical gas containers. For the purposes of this section, a “portable cryogenic medical gas container” is one that is capable of being transported and is intended to be attached to a medical gas supply system within a hospital, healthcare entity, nursing home, other facility, or home healthcare setting, or is a base unit used to fill small cryogenic gas containers for use by individual patients. The term does not include cryogenic containers that are not designed to be connected to a medical gas supply system, e.g., tank trucks, trailers, rail cars, or small cryogenic gas containers for use by individual patients (including portable liquid oxygen units as defined at §868.5655 of this chapter). (2) Label and coloring requirements. The labeling specified at §201.328(a) of this chapter must be affixed to the container in a manner that does not interfere with other labeling and such that it is not susceptible to becoming worn or inadvertently detached during normal use. Each such label as well as materials used for coloring medical gas containers must be reasonably resistant to fading, durable when exposed to atmospheric conditions, and not readily soluble in water.

    Medical Device cGMP 820.30(f) Design verification. 820.120 Device labeling
    Comments: Indeed, the Medical Device cGMP requirements address labeling requirements, though the mandates for medical gas containers and connections, as well as color additives are not specified. However, the requirements for medical gasses and color additives, when applicable, would be addressed through the Medical Device design process. Labeling is tackled specifically in 820.120 Device Labeling, paragraph (a), which reads “Each manufacturer shall establish and maintain procedures to control labeling activities. (a) Label integrity. Labels shall be printed and applied so as to remain legible and affixed during the customary conditions of processing.”

    Finally, it is particularly notable that the Pharmaceutical cGMP requirements Subpart E, are specified in three sub-sections of the Medical Device cGMP requirements (Subparts C, G, H, K, L, and O).

    In conclusion, I believe  both industries’ cGMP requirements are equivalent regarding the control of components, since the design controls process for medical devices that require product containers and closures would lead to equivalent mandates. 

    Further Reading
    Review any of the other sections of this series by clicking on its headline.
    Current Good Manufacturing Practices: Pharma vs. Device
    Comparing cGMP Pharma vs. Device: Subpart A – General Provisions
    Comparing cGMP Pharma vs. Device: Subpart A—General Provisions (Part II)
    Comparing cGMP Pharma vs. Device: Subpart B—Organization and Personnel
    Comparing cGMP Pharma vs. Device: Subpart C—Buildings and Facilities and Subpart D—Equipment
     

    James A. “Jim” Dunning’s consulting career began in 2001. He has provided quality and regulatory consulting services for various companies ranging from Fortune 500 medical device firms to startups. Dunning’s passion, however, lies with startups and small companies, especially those in regulatory distress. He has amassed significant experience in preparing 510(k) applications, developing complete Quality Management Systems, providing Quality System Training, and advising on quality, business, and leadership issues. Dunning is a senior member of the American Society for Quality (ASQ) and a member of the Regulatory Affairs Professional Society (RAPS). He can be reached at jdunning@qpcservices.com.  
    Related Searches
    • pharmaceutical
    • body
    • Manufacturing
    • development
    Suggested For You
    Benefits of Outsourcing IVD Assay Manufacturing Benefits of Outsourcing IVD Assay Manufacturing
    Comparing cGMP Pharma vs. Device: Subpart C—Buildings and Facilities and Subpart D—Equipment  Comparing cGMP Pharma vs. Device: Subpart C—Buildings and Facilities and Subpart D—Equipment
    Comparing cGMP Pharma vs. Device:  Subpart B—Organization and Personnel Comparing cGMP Pharma vs. Device: Subpart B—Organization and Personnel
    Comparing cGMP Pharma vs. Device: Subpart A—General Provisions (Part II) Comparing cGMP Pharma vs. Device: Subpart A—General Provisions (Part II)

    Related Online Exclusives

    • Contract Manufacturing | Diagnostics
      Benefits of Outsourcing IVD Assay Manufacturing

      Benefits of Outsourcing IVD Assay Manufacturing

      Commercialization of new diagnostic tests often requires a contract manufacturer that can fill in the gaps in development.
      Taryn Reynolds, VP, Operations and Technology, Corgenix Inc. 12.20.17

    • Comparing cGMP Pharma vs. Device: Subpart C—Buildings and Facilities and Subpart D—Equipment

      Comparing cGMP Pharma vs. Device: Subpart C—Buildings and Facilities and Subpart D—Equipment

      ...
      James A. Dunning, Owner, QPC Services LLC 10.05.17

    • Comparing cGMP Pharma vs. Device:  Subpart B—Organization and Personnel

      Comparing cGMP Pharma vs. Device: Subpart B—Organization and Personnel

      ...
      James A. Dunning, QPC Services LLC 09.01.17


    • Comparing cGMP Pharma vs. Device: Subpart A—General Provisions (Part II)

      Comparing cGMP Pharma vs. Device: Subpart A—General Provisions (Part II)

      ...
      James A. Dunning, QPC Services LLC 07.26.17

    Loading, Please Wait..

    Trending
    • MO SCI Acquires Assets Of 3M’s Advanced Materials Business
    • Positive Long-Term Prospects For Japanese Diabetes Care Market
    • CGM Devices Could Become Main Glucose Monitoring Solution In U.S.
    • The Future Of Biomedical Engineering Advancements
    • Endologix Shares Positive 12-Month Results Of DETOUR-2 Trial
    Breaking News
    • PDC Unveils New Brand Identity
    • MD&M West News: Teamvantage Launches New Parent Company
    • BD Receives EUA from FDA for COVID-19, Influenza A/B, RSV Combination Test
    • Qosina Names Lee Pochter as Executive Vice President
    • FDA Okays Early Feasibility Study for Anteris' TAVR Product
    View Breaking News >
    CURRENT ISSUE

    January/February 2023

    • Struggling Suppliers in Electronics Manufacturing Services (EMS)
    • Machining & Laser Processing Have Huge Parts to Play
    • Medtech R&D Teams Must Be Creative & Resilient to Survive
    • Medtronic Neuromodulation President, Nnamdi Njoku, Interview
    • 6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Tocotrienols May Have Protective Effect on Liver in NAFLD Patients
    Indian Gooseberry Extract Shown to Offer Blood Sugar Management Benefits
    ADM Expands Production to Meet Demand for Probiotics
    Coatings World

    Latest Breaking News From Coatings World

    AkzoNobel Reports Revenue Growth in 2022
    Orion Engineered Carbons Announces New Distribution Partnerships
    Personnel Changes at BASF
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    PDC Unveils New Brand Identity
    MD&M West News: Teamvantage Launches New Parent Company
    BD Receives EUA from FDA for COVID-19, Influenza A/B, RSV Combination Test
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH Acquires MEDELPHARM to Strengthen R&D Product Line
    SRI Names Kathlynn Brown Biosciences Division President
    Battelle, AmplifyBio, Andelyn Biosciences Win Research Contract
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Kiss Colors & Care Taps Rapper JT as Brand Partner
    Revolution Beauty Expands into Walmart in the U.S.
    Macro-Environmental Factors Impacting the Packaging Industry
    Happi

    Latest Breaking News From Happi

    Perfect Corp. Receives MLPS 2.0-Compliant Status to Help Beauty and Fashion Brands Meet China's National Cybersecurity Standards
    Ocean Conservation Managers Convene for Fifth International Marine Protected Area Congress, Receives Private Sector Support From Mary Kay Inc.
    Mintel Reveals Macro-Environmental Factors Impacting Household and Personal Care Packaging
    Ink World

    Latest Breaking News From Ink World

    Orion Carbons Announces New Distribution Partnerships
    DuPont Reports 4Q, Full Year 2022 Results
    Graphic Packaging Reports Strong 4Q, Full Year 2022 Results
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    'Build Back the Wisconsin Paper Industry' event announced
    Magic Johnson to keynote Dscoop Edge St. Louis World Expo
    Norway's Digital Etikett grows with HP Indigo
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Edgewell’s Sales Increase
    Mitsui Chemicals, Asahi Kasei Combine Nonwovens Businesses
    Hospeco Offers TaskBrand Prep-Paint-Finish Wiping System
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    OssDsign Launches New Product for Additional Surgical Procedures
    OSSIO Introduces Non-Permanent Compression Staple
    Dennis Jones Joins Intelivation Technologies as Manufacturing VP
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Identiv Expands NFC and HF Solutions Portfolio
    HID Acquires GuardRFID to Expand Healthcare Offering
    DuPont Reports Fourth Quarter, Full Year 2022 Results

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login